TOLCENDA Trademark

Trademark Overview

On Wednesday, September 18, 2019, a trademark application was filed for TOLCENDA with the United States Patent and Trademark Office. The USPTO has given the TOLCENDA trademark a serial number of 88621127. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 3, 2023. This trademark is owned by Pfizer Inc.. The TOLCENDA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
tolcenda

General Information

Serial Number88621127
Word MarkTOLCENDA
Filing DateWednesday, September 18, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 3, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 7, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 25, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, April 3, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 3, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, August 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 11, 2022SOU EXTENSION 5 GRANTED
Tuesday, August 2, 2022SOU EXTENSION 5 FILED
Thursday, August 11, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 2, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, February 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 7, 2022SOU EXTENSION 4 GRANTED
Monday, February 7, 2022SOU EXTENSION 4 FILED
Monday, February 7, 2022SOU TEAS EXTENSION RECEIVED
Thursday, August 5, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 3, 2021SOU EXTENSION 3 GRANTED
Tuesday, August 3, 2021SOU EXTENSION 3 FILED
Tuesday, August 3, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, February 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 1, 2021SOU EXTENSION 2 GRANTED
Monday, February 1, 2021SOU EXTENSION 2 FILED
Monday, February 1, 2021SOU TEAS EXTENSION RECEIVED
Thursday, August 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 4, 2020SOU EXTENSION 1 GRANTED
Tuesday, August 4, 2020SOU EXTENSION 1 FILED
Tuesday, August 4, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, March 3, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, February 13, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 13, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 7, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 7, 2020PUBLISHED FOR OPPOSITION
Wednesday, December 18, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, December 2, 2019ASSIGNED TO LIE
Monday, November 25, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 19, 2019EXAMINER'S AMENDMENT ENTERED
Tuesday, November 19, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, November 19, 2019EXAMINERS AMENDMENT E-MAILED
Tuesday, November 19, 2019EXAMINERS AMENDMENT -WRITTEN
Thursday, November 14, 2019ASSIGNED TO EXAMINER
Wednesday, September 25, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 21, 2019NEW APPLICATION ENTERED

Related Keywords

tolcenda preparations pharmaceutical disorders dysfunction treatment erectile sexual liver diseases viral